Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)



Status:Completed
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/31/2018
Start Date:November 2007
End Date:December 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase II Study of Sorafenib in Combination With Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer

This is an open-label, single institution, phase II study of Sorafenib in combination with
docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Docetaxel and
carboplatin will be given on day 1 of every three week cycle. Patients will take Sorafenib
twice a day on the 1st day of treatment and continue to take the medication every day until
progression of disease, prohibitive toxicity, or patient withdrawal from the study.
Chemotherapy courses will repeat every 21 days in the absence of disease progression or
unacceptable toxicity for a total of four cycles.


Inclusion Criteria:

- Histologically or cytologically confirmed NSCLC with clinical or radiological evidence
of advanced disease (Stage IIIB/IV)

- Uni-dimensionally measurable disease

- Age => 18 years

- ECOG performance status of 0-1

- Life expectancy > 3 months

Exclusion Criteria:

- Small-cell or mixed histologies including a small cell component

- Prior chemotherapy, biotherapy, radiotherapy to an area of measurable disease

- Patients with peripheral neuropathy grade => 2
We found this trial at
1
site
Abramson Cancer Center of the University of Pennsylvania
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials